The company filed a material 8-K report with the SEC, so the model re-ran its full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › ESTA
Establishment Labs Holdings Inc (ESTA) stock analysis
WEAK BUY 20% confidence · analysed Oct 15, 2026
On Oct 15, 2026, our model rated Establishment Labs Holdings Inc (ESTA) WEAK BUY with 20% confidence at a price of $57.88. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryMedical Devices
Market cap1.72B
Analysed price$57.88
Technical picture
The 14-day RSI is 29, below 30, which is oversold territory: sellers have pushed hard recently. Oversold stocks often bounce, but they can stay weak for a while.
MACD is below its signal line, so short-term momentum is pointing down.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (1.3x the 20-day average).
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $97.59 and the swing low is $53.16; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of -15.8% and revenue growth of +31.7%.
In its latest quarter it earned $-0.32 per share, which missed the $-0.30 analysts expected, with revenue +31.7% year over year.
Wall Street's average rating is 1.2 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $102.44.
The next earnings report is expected around Nov 4, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $61.13, a target of $65.94 (+7.9%) and a stop-loss at $54.67 (-10.6%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Oct 25, 2026 whatever the price does.
Entry$61.13
Target$65.94
Stop-loss$54.67
Reassess byOct 25, 2026
Research notes
ESTA’s bull case has strengthened: Q2 2026 revenue beat estimates at $67.5 million, management raised full-year revenue guidance, U.S. demand remained strong, and analysts cited market-share gains; Needham and Canaccord lifted targets to $95 and $105, respectively. A major catalyst is FDA approval of 28 additional Motiva implant sizes, expanding the U.S. product range, while the extended silicone supply agreement through 2031 improves supply visibility. The bear case remains execution and profitability risk: adjusted EPS loss of $0.39 exceeded the expected $0.34 loss, and the company still needs to deliver projected positive free cash flow in the second half of 2026. Public fundamentals agree with the prior positive view, but price action does not: shares fell 7.28% over the past week, 13.12% over the past month, and 19.8% year-to-date despite the favorable operating updates.
The model's one-paragraph read
Leans BUY — composite score +0.20 (WEAK BUY). Technicals: RSI 29.08, MACD bearish, price below SMA50. Fundamentals: margin -15.8%, revenue growth 31.7%. Financial results: YoY revenue +31.7%, last EPS surprise -6.7%, next earnings 2026-11-04. Smart Money Concepts: bullish structure intact, no fresh break. FinGPT news read: positive. Memory: 1 prior look(s). Internet research: ESTA’s bull case has strengthened: Q2 2026 revenue beat estimates at $67.5 million, management raised full-year revenue guidance, U.S. demand remained strong, and analysts cited market-share gains; Needham and Canaccord lifted targets to $95 and $105, respectively. A major catalyst is FDA approval of 28 additional Motiva implant sizes, expanding the U.S. product range, while the extended silicone supply agreement through 2031 improves supply visibility. The bear case remains execution and profitability risk: adjusted EPS loss of $0.39 exceeded the expected $0.34 loss, and the company still needs to deliver projected positive free cash flow in the second half of 2026. Public fundamentals agree with the prior positive view, but price action does not: shares fell 7.28% over the past week, 13.12% over the past month, and 19.8% year-to-date despite the favorable operating updates. Suggested levels: entry $61.13, target $65.94, stop-loss $54.67, exit by 2026-10-25 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for ESTA
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 15, 2026 | WEAK BUY | 20% | $57.88 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on ESTA
Oct 15, 2026 · Establishment Labs Holdings Inc. files an 8-K: material agreement
Other Healthcare stocks we cover
ETON · EVH · FTRE · HALO · HUM · IART · IBRX · ICLR · IRWD · JNJ · KMDA · KRYS
Frequently asked questions
Is ESTA a buy right now?
As of Oct 15, 2026, our automated model rates Establishment Labs Holdings Inc (ESTA) WEAK BUY with 20% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for ESTA?
The model's most recent plan targets $65.94 with a stop-loss at $54.67, from an entry near $61.13.
When does Establishment Labs Holdings Inc report earnings next?
The next earnings report is expected around Nov 4, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.